239 related articles for article (PubMed ID: 25463593)
1. Type I interferonopathies: mendelian type I interferon up-regulation.
Crow YJ
Curr Opin Immunol; 2015 Feb; 32():7-12. PubMed ID: 25463593
[TBL] [Abstract][Full Text] [Related]
2. Type I interferonopathies: a novel set of inborn errors of immunity.
Crow YJ
Ann N Y Acad Sci; 2011 Nov; 1238():91-8. PubMed ID: 22129056
[TBL] [Abstract][Full Text] [Related]
3. [Type I interferonopathies].
Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
[TBL] [Abstract][Full Text] [Related]
4. Genetic interferonopathies: An overview.
Eleftheriou D; Brogan PA
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
[TBL] [Abstract][Full Text] [Related]
5. Type I interferonopathies in pediatric rheumatology.
Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
[TBL] [Abstract][Full Text] [Related]
6. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
Yu ZX; Song HM
World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
[TBL] [Abstract][Full Text] [Related]
7. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies.
Pescarmona R; Belot A; Villard M; Besson L; Lopez J; Mosnier I; Mathieu AL; Lombard C; Garnier L; Frachette C; Walzer T; Viel S
Cytokine; 2019 Jan; 113():446-452. PubMed ID: 30413290
[TBL] [Abstract][Full Text] [Related]
8. The eukaryotic elongation factor eEF1A1 interacts with SAMHD1.
Morrissey C; Schwefel D; Ennis-Adeniran V; Taylor IA; Crow YJ; Webb M
Biochem J; 2015 Feb; 466(1):69-76. PubMed ID: 25423367
[TBL] [Abstract][Full Text] [Related]
9. Aicardi-Goutières syndrome and the type I interferonopathies.
Crow YJ; Manel N
Nat Rev Immunol; 2015 Jul; 15(7):429-40. PubMed ID: 26052098
[TBL] [Abstract][Full Text] [Related]
10. The Type I Interferonopathies.
Lee-Kirsch MA
Annu Rev Med; 2017 Jan; 68():297-315. PubMed ID: 27813875
[TBL] [Abstract][Full Text] [Related]
11. RNA Editing in Interferonopathies.
Frassinelli L; Galardi S; Ciafrè SA; Michienzi A
Methods Mol Biol; 2021; 2181():269-286. PubMed ID: 32729086
[TBL] [Abstract][Full Text] [Related]
12. Characterization of samhd1 morphant zebrafish recapitulates features of the human type I interferonopathy Aicardi-Goutières syndrome.
Kasher PR; Jenkinson EM; Briolat V; Gent D; Morrissey C; Zeef LA; Rice GI; Levraud JP; Crow YJ
J Immunol; 2015 Mar; 194(6):2819-25. PubMed ID: 25672750
[TBL] [Abstract][Full Text] [Related]
13. Type I Interferonopathies: A Clinical Review.
Wang CS
Rheum Dis Clin North Am; 2023 Nov; 49(4):741-756. PubMed ID: 37821193
[TBL] [Abstract][Full Text] [Related]
14. [Type I interferonopathies. Literature review].
Picard C; Belot A
Rev Med Interne; 2018 Apr; 39(4):271-278. PubMed ID: 27659742
[TBL] [Abstract][Full Text] [Related]
15. Interferon-Stimulated Gene Expression as a Preferred Biomarker for Disease Activity in Aicardi-Goutières Syndrome.
Wang BX; Grover SA; Kannu P; Yoon G; Laxer RM; Yeh EA; Fish EN
J Interferon Cytokine Res; 2017 Apr; 37(4):147-152. PubMed ID: 28387595
[TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy.
Troedson C; Wong M; Dalby-Payne J; Wilson M; Dexter M; Rice GI; Crow YJ; Dale RC
Lupus; 2013 May; 22(6):639-43. PubMed ID: 23651859
[TBL] [Abstract][Full Text] [Related]
17. MDA5 and autoimmune disease.
Miner JJ; Diamond MS
Nat Genet; 2014 May; 46(5):418-9. PubMed ID: 24769716
[No Abstract] [Full Text] [Related]
18. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation.
La Maestra S; Frosina G; Micale RT; D'Oria C; Garibaldi S; Daga A; Pulliero A; Izzotti A
Drug Deliv Transl Res; 2018 Oct; 8(5):1345-1354. PubMed ID: 29869293
[TBL] [Abstract][Full Text] [Related]
19. Autosomal dominant IFIH1 gain-of-function mutations cause Aicardi-Goutières syndrome.
Diamond J
Clin Genet; 2014 Nov; 86(5):473-4. PubMed ID: 25080300
[TBL] [Abstract][Full Text] [Related]
20. STING palmitoylation as a therapeutic target.
Hansen AL; Mukai K; Schopfer FJ; Taguchi T; Holm CK
Cell Mol Immunol; 2019 Mar; 16(3):236-241. PubMed ID: 30796349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
